Taken together, MAEL expression was associated with inactivated anti-tumor immunity, activated pathways concerning VEGFR and PI3K-AKT-mTOR, and sensitivities to VEGFR/PI3K-AKT-mTOR inhibitors in ccRCCs. The gene discussed is AKT1; the disease is neoplasm.